[go: up one dir, main page]

ES2128055T3 - Vacuna contra infecciones de bacterias gram-negativas. - Google Patents

Vacuna contra infecciones de bacterias gram-negativas.

Info

Publication number
ES2128055T3
ES2128055T3 ES95917557T ES95917557T ES2128055T3 ES 2128055 T3 ES2128055 T3 ES 2128055T3 ES 95917557 T ES95917557 T ES 95917557T ES 95917557 T ES95917557 T ES 95917557T ES 2128055 T3 ES2128055 T3 ES 2128055T3
Authority
ES
Spain
Prior art keywords
gram
vaccine
lps
negative bacteria
against gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95917557T
Other languages
English (en)
Inventor
Apurba Bhattacharjee
Alan Cross
Erald Sadoff
Wendell Zollinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of the Army
Original Assignee
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of the Army filed Critical United States Department of the Army
Application granted granted Critical
Publication of ES2128055T3 publication Critical patent/ES2128055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA VACUNA, EFECTIVA EN LA INDUCCION DE LA PRODUCCION DE ANTICUERPOS CON LOS QUE INMUNIZAR UN SEGUNDO SUJETO PASIVAMENTE CONTRA LA INFECCION POR BACTERIA GRAM-NEGATIVA Y PATOLOGIA EN LA QUE MEDIA LPS, COMPRENDE UN COMPLEJO POLIVALENTE NO COVALENTE FORMADO ENTRE LPS PURIFICADO, DESTOXIFICADO DERIVADO DE E. COLI Y PROTEINA DE MEMBRANA EXTERIOR PURIFICADA DERIVADA DE N. MENINGITIDIS. LA MISMA VACUNA TAMBIEN INMUNIZARA ACTIVAMENTE UN SUJETO HUESPED CONTRA LAS INFECCIONES BACTERIANAS GRAM-NEGATIVAS Y PATOLOGIA EN LA QUE MEDIA LPS. ENTRE ESTAS INFECCIONES BACTERIANAS GRAM-NEGATIVAS CONTRA LAS QUE PROTEGE LA VACUNA SE INCLUYEN INFECCIONES DE MENINGOCO.
ES95917557T 1994-04-20 1995-04-20 Vacuna contra infecciones de bacterias gram-negativas. Expired - Lifetime ES2128055T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23040294A 1994-04-20 1994-04-20

Publications (1)

Publication Number Publication Date
ES2128055T3 true ES2128055T3 (es) 1999-05-01

Family

ID=22865082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95917557T Expired - Lifetime ES2128055T3 (es) 1994-04-20 1995-04-20 Vacuna contra infecciones de bacterias gram-negativas.

Country Status (9)

Country Link
US (3) US7025963B1 (es)
EP (1) EP0710118B1 (es)
AT (1) ATE173634T1 (es)
AU (1) AU2356095A (es)
DE (1) DE69506212T2 (es)
DK (1) DK0710118T3 (es)
ES (1) ES2128055T3 (es)
GR (1) GR3029477T3 (es)
WO (1) WO1995029662A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289760A1 (en) * 1997-05-16 1998-11-19 Medical Defense Technologies, Llc. Vaccine against lipopolysaccharide core
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
WO1999057280A2 (en) 1998-05-01 1999-11-11 Chiron Corporation Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
BR9910749A (pt) 1998-05-29 2001-02-13 Chiron Corp Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
EP2258851A1 (en) 1999-05-19 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
PT2275554E (pt) * 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
RU2279889C2 (ru) * 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20090220522A1 (en) * 2005-10-24 2009-09-03 Cross Alan S Detoxified Endotoxin Vaccine and Adjuvant and Uses thereof
US9616116B2 (en) * 2005-10-24 2017-04-11 University Of Maryland, Baltimore Detoxified endotoxin immunogenic compositions and uses thereof
US9475864B2 (en) * 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
US8258705B2 (en) * 2009-04-29 2012-09-04 Hubbell Incorporated Scotopically enhanced emergency light and control thereof
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
CA2781866C (en) 2009-10-12 2019-12-03 New Health Sciences, Inc. Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
CA2781874A1 (en) 2009-10-12 2011-04-21 New Health Sciences, Inc. Oxygen depletion devices and methods for removing oxygen from red blood cells
ES2959120T3 (es) 2010-08-25 2024-02-20 Hemanext Inc Método para potenciar la calidad y la supervivencia de glóbulos rojos durante el almacenamiento
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
PT3539381T (pt) 2010-11-05 2023-09-26 Hemanext Inc Irradiação de glóbulos vermelhos e armazenamento anaeróbico
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
AU2012294269B2 (en) 2011-08-10 2016-11-24 Hemanext Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
WO2014134503A1 (en) 2013-02-28 2014-09-04 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016145210A1 (en) 2015-03-10 2016-09-15 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
KR102661405B1 (ko) 2015-04-23 2024-04-25 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
MX2017014812A (es) 2015-05-18 2018-05-11 New Health Sciences Inc Metodos para el almacenamiento de sangre completa y composiciones de esta.
WO2017205590A2 (en) 2016-05-27 2017-11-30 New Health Sciences, Inc. Anaerobic blood storage and pathogen inactivation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB109688A (en) 1916-11-04 1917-09-27 Herbert Senior Vincent Improvements in Steam Jacketed Heating or Boiling Pans and like Receptacles.
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
IL82624A (en) * 1986-05-23 1993-02-21 Oread Pharmaceutical Inc Compositions for co- vaccination comprising bacterial lipopolysaccharides
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock

Also Published As

Publication number Publication date
DE69506212D1 (de) 1999-01-07
EP0710118B1 (en) 1998-11-25
US7235644B2 (en) 2007-06-26
AU2356095A (en) 1995-11-29
GR3029477T3 (en) 1999-05-28
DK0710118T3 (da) 1999-08-09
US7018636B1 (en) 2006-03-28
US20060159702A1 (en) 2006-07-20
ATE173634T1 (de) 1998-12-15
WO1995029662A2 (en) 1995-11-09
EP0710118A1 (en) 1996-05-08
US7025963B1 (en) 2006-04-11
WO1995029662A3 (en) 1995-11-30
DE69506212T2 (de) 1999-08-05

Similar Documents

Publication Publication Date Title
ES2128055T3 (es) Vacuna contra infecciones de bacterias gram-negativas.
Doring et al. Virulence factors of Pseudomonas aeruginosa
GB9513074D0 (en) Novel anigen
AU1915995A (en) Active immunization using a siderophore receptor protein
Anwar et al. Outer membrane antigens of mucoid Pseudomonas aeruginosa isolated directly from the sputum of a cystic fibrosis patient
EA200100565A1 (ru) Новые стрептококковые антигены
PT754050E (pt) Metodos e materiais contra bacterias gram-positivas
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
Williams et al. Protein antigens of Staphylococcus epidermidis grown under iron-restricted conditions in human peritoneal dialysate
Anwar et al. Antibody response to acute Pseudomonas aeruginosa infection in a burn wound
Ala'Aldeen et al. Immunogenicity and cross-reactivity of the 70-Kda iron-regulated protein of Neisseria meningitidis in man and animals
DK0776214T3 (da) Antibakterialt præparat indeholdende multimert alfa-lactalbumin
El-Shahawy et al. Peritoneal dialysis-associated peritonitis caused by Alcaligenes xylosoxidans
Limjoco-Antonio et al. Arcanobacterium haemolyticum sinusitis and orbital cellulitis
Rupp et al. Hemagglutination by Staphylococcus aureus strains responsible for human bacteremia or bovine mastitis
Barton et al. Further characterization of Renibacterium salmoninarum extracellular products
PT852497E (pt) Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
HUP0000146A2 (hu) Eljárás Streptococcus pneumoniae-fertőzés kezelésére
Tambawala et al. Continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis in a child: a rare case of peritonitis caused by sphingomonous paucimobilis
Lång et al. The maltose-inducible 43 kDa major outer membrane protein in Vibrio cholerae is immunogenic and common to different isolates
RU95120818A (ru) Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
Ludovici et al. Column chromatography and cell culture assay of Pseudomonas aeruginosa toxin Z preparations
KILIAN 1. Bacterial interference with mucosal immunity
Baker Neutrophil bactericidal activity against Actinobacillus actinomycetemcomitans: The effects of antibiotics and the contribution of opsonins.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710118

Country of ref document: ES